Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by wildbird1on Aug 31, 2018 11:05am
143 Views
Post# 28548667

RE:Couple of notes from recent conference call:

RE:Couple of notes from recent conference call:'' In the hundreds of thousands ''

That would be huge.


greenergy wrote:
 
“Fully expect within this quarter and next quarter to begin implementation into large health care systems. So definitely by year end we expect to have things to say. That does not mean that we haven’t already started with some of these processes. It just means the point that we announce them you will know we are already under way”
 
“It remains an intention of ours to break even by year end. I think it will depend on what happens and how it’s happens for how much we exceed that. But, at this point our objective is still to break even. As we’ve said that the 3,000 to 4,000 mark, so that remains an objective.”
 
“The quarter numbers across Q2, we had not yet had the acceleration we were looking for. However I can tell you that within q3, we have. We expect to have a quarter that is in the hundreds of thousands. That is as far as we are prepared to go, and we expect that to continue to accelerate into year end.”
 
“We believe we are now beginning to demonstrate growth, and we expect that will take core that (share price growth).”


Bullboard Posts